跳至主要内容
临床试验/NCT01854749
NCT01854749已完成2 期

S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study

Fudan University1 个研究点 分布在 1 个国家目标入组 57 人开始时间: 2011年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
57
试验地点
1
主要终点
Progression Free Survival

研究概览

简要总结

Assess the efficacy and safety of S1 combined with cisplatin in treatment of recurrence/metastasis of ESCC

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • there is radical cure of the cancer
  • uncontrolled chronic diarrhea and esophageal obstruction
  • Neurological or mental abnormalities Influence of cognitive ability include central nervous system metastases
  • Severe complication(s), e.g.,uncontrolled active infection,myocardial infarction,hypertension,arrhythmia,stenocardia
  • Patient who has metastasis except cured skin basal cell carcinoma and carcinoma in situ of cervix
  • accept other antitumor therapy •Female patients during their pregnant and lactation period, or patients without contraception

研究组 & 干预措施

S1 combined with cisplatin

Experimental

干预措施: S1 combined with cisplatin (Drug)

结局指标

主要结局

Progression Free Survival

时间窗: from the first cycle of treatment (day one) to two month after the last cycle

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Chang Jian Hua

Deputy director of medical oncology

Fudan University

研究点 (1)

Loading locations...

相似试验